PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133,036 | -16.5% | 12,829 | +15.3% | 0.00% | – |
| Q2 2023 | $159,368 | +37.8% | 11,129 | -31.3% | 0.00% | – |
| Q1 2023 | $115,661 | -4.9% | 16,199 | +49.4% | 0.00% | – |
| Q4 2022 | $121,658 | +3.1% | 10,843 | +1.4% | 0.00% | – |
| Q3 2022 | $118,000 | +37.2% | 10,691 | +5.3% | 0.00% | – |
| Q2 2022 | $86,000 | -45.2% | 10,149 | -12.1% | 0.00% | – |
| Q1 2022 | $157,000 | -37.9% | 11,541 | -10.1% | 0.00% | – |
| Q4 2021 | $253,000 | -35.5% | 12,839 | +5.3% | 0.00% | – |
| Q3 2021 | $392,000 | -7.8% | 12,197 | -3.0% | 0.00% | – |
| Q2 2021 | $425,000 | +52.3% | 12,569 | +69.3% | 0.00% | – |
| Q1 2021 | $279,000 | +4.1% | 7,425 | -8.1% | 0.00% | – |
| Q4 2020 | $268,000 | +21.8% | 8,082 | +34.5% | 0.00% | – |
| Q3 2020 | $220,000 | +21.5% | 6,011 | +9.5% | 0.00% | – |
| Q2 2020 | $181,000 | +88.5% | 5,491 | +48.0% | 0.00% | – |
| Q1 2020 | $96,000 | -20.7% | 3,710 | -5.5% | 0.00% | – |
| Q4 2019 | $121,000 | – | 3,926 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |